HLA
RNAC icon

Hamilton Lane Advisors’s Cartesian Therapeutics RNAC Stock Holding History

Hamilton Lane Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-918
Closed – – 45
2018
Q1 		$0 Sell
918
-866
-49% -$247K ﹤0.01% 47
2017
Q4 		$525K Sell
1,784
-1,254
-41% -$548K 0.27% 46
2017
Q3 		$1.66M Hold
3,038
– – 1.14% 21
2017
Q2 		$1.81M Buy
3,038
+544
+22% +$240K 0.99% 25
2017
Q1 		$1.07M Hold
2,494
– – 0.54% 34
2016
Q4 		$1.28M Buy
+2,494
New +$1.46M 0.84% 31

Other funds holding RNAC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Hamilton Lane Advisors's RNAC Position: Q2 2018 in Review

Hamilton Lane Advisors sold out of Cartesian Therapeutics (RNAC) in Q2 2018, closing a stake of 918 shares.

Hamilton Lane Advisors first reported a position in RNAC in Q4 2016 and held it in 6 quarters. The position peaked at $1.81M in Q2 2017. 57 funds tracked by Wall St. Rank hold RNAC as of Q2 2018.

  • Hamilton Lane Advisors reported no remaining Cartesian Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Hamilton Lane Advisors sold 918 Cartesian Therapeutics shares in Q2 2018.
  • Hamilton Lane Advisors first reported a position in Cartesian Therapeutics in Q4 2016 and held it in 6 quarters.
  • Hamilton Lane Advisors's Cartesian Therapeutics position peaked at $1.81M in Q2 2017.
  • 57 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2018.

Based on Hamilton Lane Advisors's 13F filing for Q2 2018, filed 31 Jul 2018.